BindingDB logo
myBDB logout

43 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28103022 36 Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.EBI Vanderbilt University
27161876 41 Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists.EBI Shanghai Institute of Materia Medica
26303893 93 A novel series of indazole-/indole-based glucagon receptor antagonists.EBI Merck Research Laboratories
26271588 19 Recent progress in the development of small-molecule glucagon receptor antagonists.EBI Pfizer Inc.
25127101 26 Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.EBI Dainippon Sumitomo Pharma. Co. Ltd
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
24527772 262 The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.EBI Merck Research Laboratories
23562063 32 The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.EBI Pfizer Inc.
22650618 4 Rediocide A, an Insecticide, induces G-protein-coupled receptor desensitization via activation of conventional protein kinase C.EBI Chinese Academy of Sciences
22708876 106 Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.EBI Merck Research Laboratories
19597507 62 A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.EBI Indiana University
19702274 31 Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.EBI Bristol-Myers Squibb Company Research& Development
22119466 38 A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.EBI Pfizer Inc.
22030028 55 Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.EBI Merck Research Laboratories
22001094 78 Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.EBI Merck Research Laboratories
21147532 82 Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.EBI Merck Research Laboratories
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
18707090 68 Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.EBI Novo Nordisk A/S
18539028 81 Discovery of potent, orally active benzimidazole glucagon receptor antagonists.EBI Merck Research Laboratories
15387654 3 BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp.EBI Boehringer Ingelheim Pharma GmbH and Co. KG
17201415 47 New beta-alanine derivatives are orally available glucagon receptor antagonists.EBI Novo Nordisk A/S
17126016 69 Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.EBI Merck Research Laboratories
16500101 3 Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.EBI Central Drug Research Institute
16250656 4 Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension.EBI Pharmacopeia Inc.
16102966 55 Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.EBI Merck Research Laboratories
15713396 22 Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.EBI Merck Research Laboratories
15080976 43 Biaryl amide glucagon receptor antagonists.EBI Abbott Laboratories
12477359 78 Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.EBI Novo Nordisk A/S
12419375 21 Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.EBI Bayer Research Center
11965376 19 Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.EBI Bayer Research Center
11844695 35 Human glucagon receptor antagonists based on alkylidene hydrazides.EBI Pfizer Global Research and Development
11814820 28 Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.EBI Bayer Research Center
11549467 85 Substituted imidazoles as glucagon receptor antagonists.EBI Merck Research Laboratories
11543683 42 Identification of alkylidene hydrazides as glucagon receptor antagonists.EBI Pfizer Global Research and Development
10201821 166 Potent, orally absorbed glucagon receptor antagonists.EBI Merck Research Laboratories
9857085 33 Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.EBI Novo Nordisk A/S
28376304 26 Origins of PDZ Binding Specificity. A Computational and Experimental Study Using NHERF1 and the Parathyroid Hormone Receptor.BDB The University of Queensland
21108268 67 Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.BDB Eberhard Karls University of Tuebingen